Huafeng Wang

14PUBLICATIONS
30CO-AUTHORS
Haematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (14)

|Aug 21, 2026
Oncogenic DHX15 mutation enhances mitochondrial metabolism and sustains leukemia stemness.

|Jun 02, 2026
Optimizing treatment selection and timing of allogeneic haematopoietic stem cell transplantation in acute myeloid leukaemia with concurrent feline McDonough sarcoma (FMS)-like tyrosine kinase 3 internal tandem duplication, nucleophosmin 1 and deoxyribonucleic acid (DNA) methyltransferase 3 alpha mutations.

|Feb 28, 2024
Venetoclax plus daunorubicin and cytarabine in newly diagnosed acute myeloid leukemia patients: A propensity score-matched analysis.

Rong Wang, Yi Zhang, Jie Chang

|Feb 24, 2024
Etoposide combined with cytarabine and pegfilgrastim for poorly mobilizing patients with multiple myeloma and lymphoma: A prospective multicentre study.

Peipei Ye, Yixuan Cheng, Jiaying Lian

|Dec 31, 2023
Phosphoproteomic Characterization and Kinase Signature Predict Response to Venetoclax Plus 3+7 Chemotherapy in Acute Myeloid Leukemia.

Jie Jin, Shangyu Hou, Yiyi Yao

|Nov 08, 2023
Gilteritinib-based combination therapy in adult relapsed/refractory FLT3-mutated acute myeloid leukaemia.

Nianci Chen, Jiajia Pan, Yile Zhou

Pageof 3

Frequent Collaborators

11 joint publications

Jie Jin

7 joint publications

Hongyan Tong

4 joint publications

Yinjun Lou

3 joint publications

Yi Zhang